Neuropathic pain — pain caused by lesions or disease of the somatosensory nervous system — is one of the most common and disabling pain conditions in neurology. It includes diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, central post-stroke pain, spinal cord injury pain, complex regional pain syndrome, chemotherapy-induced peripheral neuropathy, and many others. Effective management requires understanding both peripheral and central mechanisms, and selecting from anticonvulsants, antidepressants, topical agents, and adjuvant therapies. This page covers the modern approach to neuropathic pain.

First-Line Therapies

α2δ Calcium Channel Ligands

  • Gabapentin: 300 mg → 3600 mg/day (TID); first-line for many neuropathic conditions.
  • Pregabalin: 75 mg BID → 600 mg/day; linear pharmacokinetics; faster onset than gabapentin.
  • Mechanism: bind α2δ subunit of voltage-gated Ca²⁺ channels → reduce presynaptic neurotransmitter release.
  • Approved indications:
    • Gabapentin: post-herpetic neuralgia.
    • Pregabalin: diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, neuropathic pain associated with SCI.
  • Side effects: sedation, dizziness, peripheral edema, weight gain.
  • Renal dose adjustment essential.
  • Pregabalin: Schedule V (abuse potential).
  • Onset: 1-2 weeks; full effect 4-8 weeks.

Tricyclic Antidepressants

  • Amitriptyline: 10-100 mg HS; gold standard for neuropathic pain; lower doses than for depression.
  • Nortriptyline: alternative; less anticholinergic burden.
  • Desipramine: alternative.
  • Mechanism: SERT/NET inhibition + Na⁺ channel block + anticholinergic.
  • Side effects: anticholinergic (dry mouth, constipation, urinary retention, orthostasis, cognitive), QT prolongation, cardiac conduction in overdose.
  • Avoid in elderly, glaucoma, urinary retention, conduction disease.
  • Nortriptyline often preferred in elderly.

Serotonin-Norepinephrine Reuptake Inhibitors

  • Duloxetine: 60-120 mg/day; FDA-approved for diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain, low back pain, osteoarthritis pain.
  • Venlafaxine: 150-225 mg/day (need higher doses for NE effect).
  • Milnacipran: fibromyalgia.
  • Mechanism: SERT + NET inhibition.
  • Side effects: nausea, sleep disturbance, BP elevation (venlafaxine), sexual dysfunction.
  • Often better tolerated than TCAs.

Second-Line Therapies

Other Anticonvulsants

  • Carbamazepine: 100 mg → 1200 mg/day; first-line for trigeminal neuralgia.
  • Oxcarbazepine: alternative for trigeminal neuralgia; better tolerated.
  • Lamotrigine: for some neuropathic pain (central post-stroke).
  • Topiramate: alternative.
  • Lacosamide: some evidence.

Tramadol

  • Weak opioid + serotonergic effects.
  • 50-100 mg q4-6h; max 400 mg/day.
  • Side effects: seizures (lowers threshold), serotonin syndrome (with SSRI), dependence.
  • Avoid combining with SSRI when possible.

Topical Agents

  • Lidocaine 5% patch: post-herpetic neuralgia; up to 3 patches × 12 hours daily.
  • Capsaicin 8% patch: targeted application; transient burning; longer-lasting effect; restricted use.
  • Diclofenac topical: localized musculoskeletal pain.
  • Useful for localized neuropathic pain; minimal systemic side effects.

Third-Line / Refractory

Strong Opioids

  • Generally NOT recommended for chronic neuropathic pain (poor evidence vs side effect/dependence risk).
  • Methadone: NMDA antagonism component; emerging evidence in select neuropathic conditions.
  • Tapentadol: opioid + NET inhibition; oral; alternative.
  • If used: trial period; clear treatment goals; monitor for misuse; opioid agreement.

Other Agents

  • NMDA antagonists: ketamine infusions emerging for refractory neuropathic pain.
  • Cannabinoids: nabiximols (UK/Canada) for MS spasticity-related pain; oral synthetic; mixed evidence.
  • Botulinum toxin: localized neuropathic pain; trigeminal autonomic cephalalgias.
  • α2 agonists: tizanidine, clonidine.
  • Mexiletine: oral Na⁺ channel blocker; uncommon use.

Specific Neuropathic Pain Conditions

Diabetic Peripheral Neuropathy

  • First-line: pregabalin, duloxetine, gabapentin.
  • Second-line: TCAs, tramadol, topical lidocaine.
  • Glycemic control important but neuropathy may not reverse.
  • Tapentadol approved.

Post-Herpetic Neuralgia (PHN)

  • Prevention: shingles vaccination (RZV recombinant); acute zoster treated with antivirals.
  • First-line: gabapentin/pregabalin; TCAs; lidocaine patch.
  • Second-line: capsaicin patch, opioids in selected.

Trigeminal Neuralgia

  • Carbamazepine: first-line (start 100 mg BID).
  • Oxcarbazepine: better tolerated alternative.
  • Lamotrigine, baclofen, gabapentin: alternatives.
  • Surgical: microvascular decompression, gamma knife, percutaneous balloon compression.

Central Post-Stroke Pain

  • Amitriptyline first-line.
  • Lamotrigine: emerging evidence.
  • Pregabalin alternative.
  • Difficult to treat; often refractory.

Spinal Cord Injury Pain

  • Pregabalin, gabapentin first-line.
  • Amitriptyline alternative.
  • Multidisciplinary approach (rehabilitation, neurostimulation).

Chemotherapy-Induced Peripheral Neuropathy

  • Duloxetine: emerging evidence.
  • Pregabalin, gabapentin: limited evidence.
  • Topical menthol some benefit.
  • Most importantly: prevention through dose modification.

Complex Regional Pain Syndrome (CRPS)

  • Multimodal: PT/OT critical.
  • Anti-inflammatory; bisphosphonates (early).
  • Gabapentin/pregabalin, antidepressants.
  • Sympathetic nerve blocks; spinal cord stimulation.
  • Refractory: ketamine; immunotherapy in some.

HIV-Related Peripheral Neuropathy

  • Gabapentin/pregabalin; topical agents.
  • Modification of antiretrovirals if drug-induced.

Pain in Multiple Sclerosis

  • Trigeminal neuralgia common in MS: carbamazepine first-line.
  • Lhermitte’s sign / dysesthesias: gabapentin.
  • Painful tonic spasms: gabapentin, baclofen.
  • Central pain: amitriptyline.

Pain in Parkinson Disease

  • Off-period pain: optimize levodopa.
  • Central pain: gabapentinoids, SNRIs.
  • Musculoskeletal: standard.
  • Dystonic pain: botulinum toxin.

Fibromyalgia

  • First-line: duloxetine, milnacipran, pregabalin (FDA-approved).
  • Amitriptyline second-line.
  • Exercise: critical.
  • CBT: effective.
  • Address sleep, mood.

Combination Therapy

  • Combine drugs with different mechanisms when monotherapy fails.
  • Gabapentin + opioid: caution (cognitive, respiratory).
  • Gabapentin + TCA: often beneficial.
  • SNRI + topical lidocaine: targeted approach.
  • Polypharmacy adds cumulative burden.

Interventional / Non-Pharm

  • Nerve blocks: diagnostic and therapeutic.
  • Spinal cord stimulation: failed back surgery, CRPS, painful diabetic neuropathy.
  • DRG stimulation: emerging for localized neuropathic pain.
  • Sympathetic blocks.
  • Intrathecal pumps: morphine, ziconotide.
  • Acupuncture, TENS.
  • CBT, mindfulness-based stress reduction.

🔍 Did You Know?

The growing recognition that pregabalin and gabapentin have abuse potential and respiratory depression risk when combined with opioids has reshaped how these “first-line” neuropathic pain drugs are prescribed. For decades, gabapentin and pregabalin were considered relatively benign — non-controlled in the US (with pregabalin Schedule V) — and were heavily prescribed for various pain conditions. However, post-marketing data has revealed substantial issues: gabapentinoids are widely used off-label for opioid potentiation, are involved in increasing opioid-related deaths (cumulative respiratory depression), and have abuse potential particularly in patients with substance use disorders. The FDA has issued warnings about gabapentinoid + opioid combinations, particularly in respiratory conditions. The clinical implications: gabapentinoids should be prescribed with careful consideration of co-prescribed opioids, sleep apnea, and substance use history. For practicing neurologists, the cautions include: (1) avoid combining with opioids when possible; (2) lower doses in elderly and renal impairment; (3) screen for substance use; (4) consider tapering before discharge from acute care; (5) educate patients about respiratory depression risk; (6) Schedule V status of pregabalin in US prompts more cautious prescribing. The lesson generalizes: drugs that initially appear benign may prove to have important safety signals after years of widespread use, and pharmacovigilance is ongoing throughout a drug’s lifecycle. The neuropathic pain field has not abandoned gabapentinoids but has matured in how they are prescribed.

Pitfalls and Pearls

  • First-line: gabapentin, pregabalin, duloxetine, TCAs.
  • Gabapentin titration: requires gradual titration; full effect 4-8 weeks.
  • Pregabalin: linear PK; faster onset; Schedule V.
  • Amitriptyline: gold standard TCA; low dose for pain (10-100 mg).
  • Nortriptyline: less anticholinergic; preferred in elderly.
  • Duloxetine: FDA-approved diabetic neuropathy, fibromyalgia.
  • Venlafaxine: NE effect needs higher doses (≥150 mg).
  • Lidocaine 5% patch: post-herpetic neuralgia; localized.
  • Capsaicin 8% patch: refractory; transient burning; specialized application.
  • Carbamazepine: trigeminal neuralgia first-line.
  • Tramadol: SSRI interaction (serotonin syndrome); seizure threshold.
  • Opioids for neuropathic pain: generally avoid chronically.
  • Gabapentinoid + opioid: respiratory depression risk; FDA warning.
  • Renal dose adjustment: gabapentin, pregabalin require substantial reduction.
  • Fibromyalgia: duloxetine, milnacipran, pregabalin FDA-approved.
  • Combination therapy: different mechanisms often beneficial.
  • Topical agents: under-utilized; localized neuropathic pain.
  • Non-pharm: PT, CBT, exercise critical adjuncts.

References

  1. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
  2. Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328-335.
  3. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
  4. Goodman CW, Brett AS. Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411-414.
  5. Argoff CE. Topical analgesics for the management of acute and chronic pain. Mayo Clin Proc. 2013;88(2):195-205.